1h Free Analyst Time
The sinusitis drugs market is forecasted to grow by USD 735.7 million during 2023-2028, accelerating at a CAGR of 5.53% during the forecast period. The report on the sinusitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of sinusitis, growing awareness among people about sinusitis treatment, and increasing mergers and acquisitions among vendors.
The sinusitis drugs market is segmented as below:
By Product
- Steroid nasal sprays
- Antibiotics
- Decongestants
- Others
By Disease Type
- Acute sinusitis
- Chronic sinusitis
- Sub-acute sinusitis
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the sinusitis drugs market covers the following areas:
- Sinusitis drugs market sizing
- Sinusitis drugs market forecast
- Sinusitis drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Disease Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global sinusitis drugs market: AbbVie Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Bayer AG, Bionpharma Inc., CHIESI Farmaceutici SpA, Cipla Inc., Dr Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Neopharma Corp., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teligent Inc., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing investments in research and development by major players."
According to the report, one of the major drivers for this market is the rising prevalence of sinusitis.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alembic Pharmaceuticals Ltd.
- Aurobindo Pharma Ltd.
- Bayer AG
- Bionpharma Inc.
- CHIESI Farmaceutici SpA
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- Fresenius SE and Co. KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals Plc
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Neopharma Corp.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teligent Inc.
- Teva Pharmaceutical Industries Ltd.
